50881-48-6

Basic information

• Product Name: N-chlorosulfonyl-N'-phenyl-urea
• Synonyms: N-chlorosulfonyl-N'-phenyl-urea
• CAS NO: 50881-48-6
• Molecular Weight: 234.663
• Mol File: 50881-48-6.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N-chlorosulfonyl-N'-phenyl-urea(CAS DataBase Reference)
• NIST Chemistry Reference: N-chlorosulfonyl-N'-phenyl-urea(50881-48-6)
• EPA Substance Registry System: N-chlorosulfonyl-N'-phenyl-urea(50881-48-6)

Safety Data

• Hazardous Substances Data: 50881-48-6(Hazardous Substances Data)

Upstream product

• 1189-71-5 isocyanate de chlorosulfonyle 
• 62-53-3 aniline 

Downstream Products

• 3306-62-5 2-AMINOBENZENESULFONAMIDE 
• 222420-33-9 ethyl ester 2-aminosulfonylanilide of 2-sulfonylmalonic acid 
• 53971-22-5 (1,1-dioxo-1,4-dihydro-1λ⁶-benzo-[1,2,4]-thiadiazin-3-yl)acetic acid ethyl ester 
• 686263-53-6 1-benzyl-3-(1,1-dioxido-4H-1,2,4-benzothiadiazin-3-yl)-4-hydroxy-1,8-naphthyridin-2(1H)-one 
• 59794-92-2 ethyl 2-oxo-2-((2-sulfamoylphenyl)amino)acetate 
• 13338-00-6 2H-1,2,4-benzothiadiazin-3(4H)-one 1,1-dioxide 
• 4886-26-4 N-phenyl-N'-phenylsulfamoyl-urea 

Relevant articles and documents

"a Sweet Combination": Developing Saccharin and Acesulfame K Structures for Selectively Targeting the Tumor-Associated Carbonic Anhydrases IX and XII

The sweeteners saccharin (SAC) and acesulfame K (ACE) recently entered the topic of anticancer human carbonic anhydrase (CA, EC 4.2.1.1) inhibitors, as they showed to selectively inhibit the tumor-associated CAs IX/XII over ubiquitous CAs. A drug design s

Synthesis and pharmacological activity of N-(2,2-dimethyl-3,4-dihydro-2H-1- benzopyran-4-yl)-4H-1,2,4-benzothiadiazine-3-carboxamides 1,1-dioxides on rat uterus, rat aorta and rat pancreatic β-cells

N-(2,2-Dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4H-1,2, 4-benzothiadiazine-3-carboxamides 1,1-dioxides were prepared and evaluated on rat uterus, rat aortic rings and rat pancreatic β-cells. Pharmacological studies conducted on rat uterus indicated that several of these original hybrid compounds displayed a strong myorelaxant activity. The most active compounds hold a bromine atom at the 6-position of the dihydrobenzopyran ring. Moreover, the compounds failed to display a marked inhibitory effect on insulin secretion and vascular myogenic activity. These features suggest that the 6-bromo compounds could be relatively selective towards the uterine smooth muscle.

Inhibitors of HCV NS5B polymerase: Synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring

A series of non-nucleoside HCV NS5B polymerase inhibitors based on the N-1-benzyl or N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine core substituted in the D-ring aromatic moiety have been prepared and evaluated. Aromatic substituents extending from position 7 of the D-ring exhibited excellent potency against both genotypes 1a and 1b.